RavenDB and QBS Software Announce Strategic Partnership to Expand NoSQL Innovation Across UK and Europe
RavenDB, the pioneer of hybrid NoSQL document databases for modern applications, today announced a strategic partnership with QBS Software, a leading software distributor with a robust network of resellers and system integrators across the UK and Europe. This alliance is set to accelerate the adoption of RavenDB’s high-performance, developer-first data platform throughout the region.
As part of the partnership, QBS will offer RavenDB solutions through its extensive channel ecosystem, enabling more organizations to build responsive, intelligent applications powered by RavenDB’s unmatched performance, hybrid deployment model, and frictionless developer experience.
“RavenDB empowers the QBS community to build faster, smarter, and more cost-efficient applications,” said David Baruc, Chief Revenue Officer at RavenDB. “By combining a flexible document model with built-in full-text search, automatic indexing, and seamless deployment across cloud, on-prem, and edge, we eliminate the need for multiple tools and reduce infrastructure costs and overhead. It’s a modern solution built for real-time performance at scale with a strong ease of use.”
RavenDB is trusted by Fortune 500s, global ISVs, and innovative startups to manage mission-critical data without compromising speed, flexibility, or cost-efficiency. The platform’s built-in distributed architecture and zero-touch operational overhead allow teams to focus on building applications, not managing infrastructure.
For QBS Software, the partnership solidifies their reputation as a forward-looking, full spectrum software distributor with a commitment to innovation and strategic growth.
Ikramul Khaled, Group Head of Vendor Alliances at QBS Technology Group:
“RavenDB enhances the publisher portfolio for QBS Software by adding a high-performance, flexible and scalable NoSQL database solution. With RavenDB being optimised for speed and low-latency performance, especially in distributed systems and cloud environments, this gives QBS a competitive edge in offering scalable database solutions to our partners.”
As part of the go-to-market collaboration, RavenDB and QBS will jointly host educational webinars, training programs, and partner enablement sessions aimed at accelerating time-to-value for customers and resellers alike.
To learn more about the RavenDB-QBS partnership visit ravendb.net/partners.
About RavenDB
RavenDB is the hybrid NoSQL document database built for modern application development. Used by 12,000 companies across 50 industries, RavenDB helps teams move faster with seamless data management across cloud, on-prem, and edge environments. With full-text search, automatic indexes, and an easy-to-use studio for monitoring and administration, RavenDB is the database developers love and enterprises trust. Learn more at ravendb.net.
About QBS Software
QBS Software (QBS) operates the world’s largest enterprise software delivery platform, with a network of over 12,500 SaaS vendors. QBS specialises in long-tail software procurement, delivering niche and emerging software solutions. By simplifying software sourcing, procurement, and delivery, QBS empowers partners to focus on driving business growth. Visit qbssoftware.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250527583649/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 202531.5.2025 14:00:00 CEST | Press release
BRUKINSA plus venetoclax demonstrated high response rates and a favorable safety profile across CLL patient types in SEQUOIA Arm D, including those with high-risk del(17p) mutational statusAt 5-year follow-up of SEQUOIA Arm C, BRUKINSA monotherapy showed sustained OS and PFS benefit in hard-to-treat del(17p) CLL patients versus historical data BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today will present new data from the Arm C and D cohorts of the pivotal, global Phase 3 SEQUOIA trial of BRUKINSA® (zanubrutinib). The findings underscore the strong and consistent efficacy of BRUKINSA across CLL patient types, including high-risk mutation status. These data will be presented in two rapid oral presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. Data from the Arm D of SEQUOIA demonstrate that treatment with BRUKINSA plus venetoclax has the potential to drive progression-free survival and overall dee
Andersen Consulting tilføjer Stratence Partners30.5.2025 16:07:00 CEST | Pressemeddelelse
Andersen Consulting udvider sin platform med en samarbejdsaftale med Stratence Partners, der er et konsulentfirma med base i Storbritannien, som hjælper globale virksomheder med at øge markedsandele og forbedre rentabiliteten gennem deres ekspertise inden for prisfastsættelse, strategisk optimering, kommerciel effektivitet og digital transformation. Stratence Partners har en resultatorienteret tilgang og er forpligtet på bæredygtig forandring, hvorved de hjælper deres kunder gennem en unik kombination af konsulentbistand, midlertidige ledelsesindsater og oplæringskurser samt deres egne metoder og løsninger inden for datastyring, datavidenskab (AI), værktøjer og systemer. "Samarbejdet med Andersen Consulting er et spændende skridt for vores firma," sagde Fernando Ventureira, administrerende direktør for Stratence Partners. "I vores arbejde med hos ledere over hele verden har vi erfaret, at deres behov rækker ud over strategisk prisfastsættelse og driftsoptimering. Vores kunder værdsætte
You Up? Grindr’s “Right Now” Goes Global30.5.2025 15:00:00 CEST | Press release
More places, more people – Grindr’s real-time hookup feature makes connecting faster than ever Grindr, the Global Gayborhood in Your Pocket™ with more than 14.6M average monthly active users, today announced the global launch of Right Now, their newest intent-based feature designed to instantly connect people looking for immediate encounters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250530651954/en/ Grindr's Right Now feature. Right Now is a real-time feed—separate from the app’s main grid that displays profiles—where Grindr users can post text and share photos displayed for one hour, letting other like-minded users know exactly what they’re looking for. “Right Now empowers our users to find exactly what they want, when they want it – without the guesswork,” said AJ Balance, Chief Product Officer at Grindr. “We built this intention-based feature based on feedback from our community so they can connect with like-minded
CAR T Vision Coalition Launches with Ambitious Goal to Double Patients Treated with the Curative Potential of CAR T-cell Therapy by 203030.5.2025 14:00:00 CEST | Press release
Only approximately 2 out of 10 people in the US and 3 out of 10 people in Europe with certain rare, advanced blood cancers receive access to CAR T-cell therapy1,2,3New roadmap report aims to inspire collective action of stakeholder groups and invites additional CAR T-cell therapy leaders to join the coalition Today an international coalition announces the launch of CAR T Vision to unite stakeholders around the shared ambition that every eligible patient should have the opportunity for cure with CAR T-cell therapy. By 2030, the aim is to double the proportion of eligible patients treated with CAR T-cell therapy. As outlined in the new roadmap report, the coalition will work to address access challenges and drive meaningful change in the CAR T-cell therapy healthcare ecosystem with a focus on three critical priorities: increasing awareness and understanding of CAR T-cell therapy; expanding resources and capacity to deliver CAR T-cell therapy; and developing sustainable and innovative fin
Indian Educationist Dr. Achyuta Samanta Recognised With Research Institute in His Name at CUNY, USA30.5.2025 11:17:00 CEST | Press release
In a noteworthy development underscoring growing academic collaboration between India and the United States, the City University of New York (CUNY) has launched a dedicated research platform—the Achyuta Samanta India Initiative of the CUNY CREST Institute (ASIICCI). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529012005/en/ Dr. Milton Santiago, President of Bronx Community College, and Dr. Achyuta Samanta, Founder of KIIT & KISS, jointly inaugurate the Achyuta Samanta India Initiative of CUNY CREST Institute (ASIICCI) with a ribbon-cutting ceremony in New York. Named after Dr. Achyuta Samanta, a noted Indian educationist and social worker, the initiative focuses on academic research in Indian social and educational sectors, with a particular lens on Odisha. This marks one of the rare instances of a living Indian being honoured with such a naming in an American public university system. Dr. Samanta, who hails from Odisha
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom